Axio Biosolutions, a Bengaluru-based biomaterial focused medtech company, has announced the US Food and Drug Administration (FDA) 510(k) clearance for its latest innovation, Ax-Surgi Surgical Hemostat. With this, Ax-surgi has become the first and only chitosan based hemostat cleared for controlling severe surgical bleeding.

Ax-Surgi is based on a novel biopolymer platform and controls bleeding through its bioadhesive action. It is indicated for temporary control of internal organ space bleeding for patients displaying Class III or Class IV bleeding. It can also be used for control of severely bleeding wounds such as surgical wounds and traumatic injuries.

As the healthcare costs continue to rise, surgeons are looking for effective measures to reduce the duration of surgeries.  These factors are propelling the demand for better and cost-effective solutions for controlling severe bleeding during the surgeries.

A number of products ranging from standard lap-sponges to absorbable hemostatic patches and sealants are available for the surgical bleeding control. Most of these are indicated to control minor bleeding and hence a major challenge for surgeons is to select a suitable hemostat that can be used in different grades of the bleedings. Many times surgeons keep multiple products opened and ready for use to manage any emergency bleeding during the surgery. This strategy inadvertently leads to increased surgery costs due to wastage of resources.

Ax-surgi will fill this gap by offering a rapid acting hemostat for controlling moderate to severe bleeding from surgical and traumatic injuries.